Next Potential Big ADC Player? Korean Firms Take It Up A Notch
Most Assets Still Early Stage
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
